Protein expression analysis in GBM patients revealed two populations of glioblastoma stem-like cells (GSC) associated with different clinical outcomes: (i) proto-oncogene, tyrosine protein kinase and SRC activation is associated with the subgroup showing better prognosis (ii) ribosomal protein S6 (RPS6), an effector of the mTOR pathway is associated with poor patient prognosis [49]. The gene discussed is RPS6; the disease is glioblastoma.